For decades, the textbook view held that inflammation simply faded away — a passive dissipation of pro-inflammatory signals once the threat had passed. That assumption collapsed in the early 2000s when Charles Serhan’s lab at Harvard discovered that resolution is not passive at all. It is an actively orchestrated biochemical program driven by a previously unknown class of lipid mediators synthesized from EPA and DHA. These molecules — resolvins, protectins, and maresins — flip the inflammatory switch from “on” to “off” through specific G-protein coupled receptors, reframing omega-3 fatty acids from mere anti-inflammatory nutrients into substrates for active resolution biology.
What Are Resolvins and Specialized Pro-Resolving Mediators?
Specialized pro-resolving mediators (SPMs) are a family of endogenous lipid signaling molecules enzymatically derived from omega-3 polyunsaturated fatty acids. The class includes resolvins (E-series from EPA, D-series from DHA), protectins (from DHA), and maresins (from DHA via macrophage biosynthesis). They were first identified by Serhan and colleagues during resolution-phase exudate analysis, where mass spectrometry revealed novel oxygenated lipid structures appearing precisely as inflammation began to subside.[1]
Unlike traditional anti-inflammatory drugs that block the initiation of inflammation (such as NSAIDs inhibiting COX enzymes), SPMs operate downstream — they accelerate the natural termination of an inflammatory episode without immunosuppression. This distinction matters clinically because chronic, unresolved inflammation underlies cardiovascular disease, neurodegeneration, metabolic syndrome, and many autoimmune conditions.[2]
How Resolvins Work
Biosynthesis from EPA and DHA: SPM production requires sequential lipoxygenation. EPA is converted to E-series resolvins (RvE1, RvE2, RvE3) primarily via aspirin-acetylated COX-2 and 5-LOX activity. DHA serves as the precursor for D-series resolvins (RvD1 through RvD6), protectin D1 (PD1/NPD1), and maresin 1 (MaR1), generated through 15-LOX and 12-LOX pathways in neutrophils, macrophages, and platelets. This biosynthesis depends on adequate tissue levels of EPA and DHA — explaining why omega-3 status influences resolution capacity.[1]
GPCR Signaling: Each SPM acts on specific G-protein coupled receptors. RvE1 binds ChemR23 (also called ERV1) and antagonizes BLT1, the leukotriene B4 receptor that drives neutrophil recruitment. RvD1 signals through ALX/FPR2 and GPR32. These receptor interactions translate lipid signals into discrete cellular programs — stopping neutrophil infiltration, enhancing macrophage efferocytosis, and promoting tissue return to homeostasis.[3]
Macrophage Class Switching: A defining action of SPMs is the polarization of macrophages from the pro-inflammatory M1 phenotype to the pro-resolving M2 phenotype. This switch increases the clearance of apoptotic neutrophils (efferocytosis), reduces production of TNF-α and IL-6, and promotes secretion of TGF-β and IL-10 — cytokines that support tissue repair.[2]
Neutrophil Trafficking: Resolvins do not kill neutrophils or suppress their initial recruitment. Instead, they impose a temporal limit — preventing excessive neutrophil infiltration after the initial response and accelerating their apoptosis and clearance once their job is done. This preserves host defense while limiting collateral tissue damage.[1]
Clinical Evidence
Cardiovascular Disease: In atherosclerotic lesions, the balance between pro-inflammatory leukotrienes and pro-resolving lipid mediators is shifted toward unresolved inflammation. Studies of human carotid plaques have shown that vulnerable, rupture-prone plaques contain significantly lower ratios of resolvins to leukotriene B4 compared with stable plaques, suggesting that defective resolution contributes to plaque instability.[4]
Periodontal Disease: Some of the most compelling translational work involves resolvin E1 in periodontitis. In animal models, topical or systemic RvE1 reversed bone loss and restored healthy tissue architecture in established disease — not merely halting progression but driving regeneration. These findings established resolution pharmacology as a viable therapeutic concept.[3]
Neuroinflammation and Pain: Resolvins exert potent analgesic effects in models of inflammatory and neuropathic pain at doses orders of magnitude lower than conventional anti-inflammatory drugs. RvD1, RvE1, and neuroprotectin D1 reduce dorsal horn neuronal sensitization and modulate microglial activation, suggesting roles in chronic pain syndromes and neurodegenerative conditions where neuroinflammation drives pathology.[5]
Omega-3 Supplementation and SPM Levels: Human studies have demonstrated that EPA and DHA supplementation increases circulating concentrations of resolvins and their precursor pathway markers (18-HEPE for E-series, 17-HDHA for D-series). This provides a mechanistic explanation for many of the benefits attributed to fish oil — the resolution of low-grade chronic inflammation rather than the simple blocking of inflammatory triggers.[2]
Safety Profile
Because SPMs are endogenous mediators that recapitulate a natural physiologic program, they have shown a remarkably benign safety profile in preclinical work. Unlike glucocorticoids or biologic immunosuppressants, resolvins do not blunt the initial immune response or impair host defense against pathogens. In fact, in animal models of bacterial infection, resolvins enhanced bacterial clearance while limiting collateral tissue injury — uncoupling resolution from immunosuppression.
For practical clinical translation, the most accessible intervention remains adequate intake of EPA and DHA to provide substrate for endogenous SPM biosynthesis. Plasma omega-3 index, EPA:arachidonic acid ratio, and direct measurement of SPM pathway markers (such as 18-HEPE and 17-HDHA) are emerging biomarkers for resolution capacity. Synthetic resolvin analogs with improved stability are in development but not yet broadly available for clinical use.
Resolvins vs Conventional Anti-Inflammatory Approaches
NSAIDs: Non-steroidal anti-inflammatory drugs inhibit COX enzymes, blocking the production of pro-inflammatory prostaglandins. However, COX-2 is also required for the biosynthesis of aspirin-triggered resolvins. This may partially explain why low-dose aspirin appears uniquely cardioprotective — it acetylates COX-2 rather than fully inhibiting it, redirecting the enzyme toward production of 15-epi-lipoxin A4 and aspirin-triggered resolvins.[1]
Corticosteroids: Glucocorticoids broadly suppress inflammatory gene transcription, providing potent symptomatic relief at the cost of immunosuppression, metabolic disruption, and impaired wound healing. SPMs achieve resolution without these tradeoffs because they activate completion of the inflammatory program rather than aborting it.
Biologic Immunomodulators: Anti-TNF, anti-IL-6, and JAK inhibitors block specific inflammatory signals and have transformed care of rheumatoid arthritis, IBD, and psoriasis. They do not, however, restore active resolution. Combining cytokine blockade with strategies that enhance endogenous SPM production is an emerging therapeutic concept.
Omega-3 Supplementation: Marketed for decades as “anti-inflammatory,” the actual mechanism appears to be pro-resolving. This reframing has clinical implications: dose, EPA-to-DHA ratio, and baseline omega-3 status may matter more than absolute milligrams, and benefits may emerge over weeks to months as tissue lipid composition and resolution capacity shift.[2]
References
- Serhan CN. “Pro-resolving lipid mediators are leads for resolution physiology.” Nature. 2014;510(7503):92-101.
- Serhan CN, Levy BD. “Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.” Journal of Clinical Investigation. 2018;128(7):2657-2669.
- Arita M, Bianchini F, Aliberti J, et al. “Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1.” Journal of Experimental Medicine. 2005;201(5):713-722.
- Fredman G, Hellmann J, Proto JD, et al. “An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques.” Nature Communications. 2016;7:12859.
- Ji RR, Xu ZZ, Strichartz G, Serhan CN. “Emerging roles of resolvins in the resolution of inflammation and pain.” Trends in Neurosciences. 2011;34(11):599-609.
